265. Lipodystrophy Clinical trials / Disease details
Clinical trials : 116 / Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04903847 (ClinicalTrials.gov) | February 2, 2021 | 9/10/2020 | Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil | Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2 | Hiv;HIV Infections;HIV Lipodystrophy;Osteoporosis;Renal Insufficiency;Weight Gain;Obesity | Drug: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | Thomas Benfield | NULL | Recruiting | 18 Years | N/A | All | 126 | Phase 4 | Denmark |
| 2 | NCT04904406 (ClinicalTrials.gov) | October 22, 2020 | 9/10/2020 | Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals | Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1 | Hiv;HIV Infections;HIV Cardiomyopathy;Weight Change, Body;HIV Lipodystrophy;Cardiovascular Diseases | Drug: Dolutegravir / Lamivudine Oral Tablet | Thomas Benfield | NULL | Recruiting | 18 Years | N/A | All | 95 | Phase 4 | Denmark |
| 3 | NCT04340388 (ClinicalTrials.gov) | September 17, 2020 | 1/4/2020 | Contribution of Dolutegravir to Obesity and Cardiovascular Disease | Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV | HIV-1-infection;Antiviral Drug Adverse Reaction;Vascular Diseases;Cardiovascular Abnormalities;Abnormality of Adipose Tissue;Body Weight Changes;Body Fat Disorder;HIV-Associated Lipodystrophy Syndrome | Drug: Dolutegravir 50 MG;Drug: Antiretroviral/Anti HIV | Augusta University | NULL | Recruiting | 18 Years | 100 Years | All | 30 | Phase 4 | United States |